ANTIPLATELET THERAPY AFTER CORONARY ARTERY BYPASS GRAFT SURGERY – UNEVENNESS OF DAILY CLINICAL PRACTICE

Antiplatelet therapy is an integral part of optimal medicamentous therapy in patients with coronary artery disease. The strategy of antiplatelet/anticoagulant therapy is adjusted (combination of drugs, dosing and duration of therapy) depending on the stage of the disease (acute coronary syndrome wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sopek-Merkaš, Ivana, Lakušić, Nenad, Fučkar, Krunoslav, Cerovec, Duško, Bešić, Kristina Marić
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2021
Materias:
Preliminary Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907948/
https://www.ncbi.nlm.nih.gov/pubmed/35282474
http://dx.doi.org/10.20471/acc.2021.60.03.26
Descripción
Sumario:Antiplatelet therapy is an integral part of optimal medicamentous therapy in patients with coronary artery disease. The strategy of antiplatelet/anticoagulant therapy is adjusted (combination of drugs, dosing and duration of therapy) depending on the stage of the disease (acute coronary syndrome with percutaneous coronary intervention, chronic coronary syndrome, or coronary surgical revascularization) and comorbidity of each patient (e.g., atrial fibrillation, left ventricular thrombus, etc.). Guidelines and clinical practice in particular are not uniform and specific regarding dual antiplatelet therapy in patients undergoing coronary artery bypass grafting, especially in the setting of chronic coronary syndrome.

Ejemplares similares